TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
TG Therapeutics' Briumvi growth and subcutaneous formulation progress have fueled takeover rumors, with Biogen, Incyte and Sanofi cited as…
NASDAQ
TGTX
1 story
$8.2B Market cap · 2026-10-07
TG Therapeutics' Briumvi growth and subcutaneous formulation progress have fueled takeover rumors, with Biogen, Incyte and Sanofi cited as…